<div>
  <ul>
    <li>
      <p>
        Biotech precision medicine drug developer Celsius Therapeutics has raised USD 83 million in total funding from an extension of a Series A funding round, previously announced in May 2018, and a Series B round. The company received funding from new and existing investors including Casdin Capital, GV, Heritage Provider Network, Amgen Ventures, and Amplitude Ventures.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The funds will be invested in its investigational new drug (IND) filing with the FDA for its first drug candidate CEL383, an antibody treatment for inflammatory bowel disease, followed by a Phase 1 clinical trial in early 2023. The funds will also support the company&rsquo;s plans to expand its oncology pipeline using its SCOPE platform to discover drug targets.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        Celsius currently has two drug discovery programs in oncology in partnership with independent pharma group Servier.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.biospace.com/article/celsius-raises-83m-to-bring-ibd-treatment-to-trial-">
      Biospace
    </a>
  </p>
  <p>
    <a href="https://medcitynews.com/2022/03/celsius-therapeutics-heats-up-with-83m-and-an-ibd-drug-on-path-to-the-clinic/">
      MedCity News
    </a>
  </p>
  <p>
    <a href="https://www.businesswire.com/news/home/20220324005079/en/Celsius-Therapeutics-Highlights-Recent-Accomplishments-and-Key-Initiatives-for-2022">
      Business Wire
    </a>
  </p>
</div>


All Updates

Celsius raises combined funding of USD 83 million